| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.4 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.4 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |